Biochemical Pharmacology volume 80, issue 5, P731-738 2010 DOI: 10.1016/j.bcp.2010.04.011 View full text
David L. Morse, Robert J. Gillies

Abstract: Targeted therapeutic and imaging agents are becoming more prevalent, and are used to treat increasingly smaller segments of the patient population. This has lead to dramatic increases in the costs for clinical trials. Biomarkers have great potential to reduce the numbers of patients needed to test novel targeted agents by predicting or identifying non-response early-on and thus enriching the clinical trial population with patients more likely to respond. Biomarkers are characteristics that are objectively mea…

expand abstract